Lupin's Oncology Spin-Out
Lupin spins out oncology programs into Kaveri Therapeutics, retaining majority 82.2% stake
Anonymous
Key Points
1
Kaveri Therapeutics was incorporated in Delaware on May 20, 2026, as a clinical-stage oncology company focused on solid tumors (including lung, pancreatic, ovarian, and CNS cancers) with no revenue or net worth at the time, led by CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce.
2
Lupin Inc. received an 82.2% equity stake in Kaveri Therapeutics and 332,000 Kaveri common shares in exchange for exclusive perpetual rights to LNP7457 (PRMT5) and LNP8701 (SOS1), positioning Lupin for future upside while transferring ongoing development costs to the new entity.
3
The deal is structured as an equity exchange rather than a cash payment, aligning Lupin’s and Kaveri’s interests through ownership in the licensee rather than a monetary upfront.
4
Regulatory disclosures confirm the transaction is not a related-party deal; NSE and BSE filings indicate there are no promoter holdings in Kaveri and Regulation 30 disclosures were made.
5
Lupin’s stock traded around ₹2,504.60 on the NSE following the announcement, with a market capitalization of about ₹1.14 lakh crore, illustrating the market reaction to the spin-out.
Lupin Limited has spun out two cancer drug programs into a new independent company called Kaveri Therapeutics Inc., securing an 82.2% equity stake worth about $1.6 million in return, according to Nasdaq. The deal, finalized July 20, 2026, transfers two clinical oncology assets — LNP7457 and LNP8701 — to the newly formed Delaware-based firm, letting Lupin offload development costs while keeping a controlling financial interest.
Kaveri will now lead global early-stage trials for the two drugs, which target solid tumors including lung, pancreatic, ovarian, and brain cancers. Both programs showed positive data at ASCO meetings in 2025 and 2026, according to Newswire.
Two Cancer Drug Programs at the Center of the Deal
LNP7457 targets a protein called PRMT5, and LNP8701 targets a protein called SOS1. Both are known as biomarker-driven assets — meaning they are designed to work in patients who carry specific biological markers. This precision approach has become a key strategy in modern cancer drug development, according to IndiaMedToday.
Kaveri was incorporated on May 20, 2026, and had no revenue or net worth at the time of the deal. It is led by CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce. The company will fund global clinical trials and plans to raise additional capital to advance both programs, according to Cantech Letter.
Lupin Gets Equity, Not Cash, in Unusual Deal Structure
Instead of a cash payment, Lupin Inc. — Lupin's US subsidiary — received an 82.2% stake in Kaveri plus 332,000 Kaveri common shares. This equity-for-rights structure aligns both companies' interests: Lupin benefits if Kaveri succeeds, while Kaveri takes on the cost and risk of running trials, according to Whalesbook.
The arrangement lets Lupin book a potential future upside from drug approvals without spending heavily on clinical development right now. It also allows Kaveri to operate independently and pursue its own global partnerships and funding rounds.
Regulatory Filings Show No Conflict of Interest
Lupin filed Regulation 30 disclosures with both the NSE and BSE in India following the deal. Filings confirm this is not a related-party transaction and that no promoter holds shares in Kaveri Therapeutics, according to IndiaMedToday. This means the deal was conducted at arm's length between independent parties.
Lupin's stock traded at around ₹2,504.60 on the NSE after the announcement, with a market capitalization of roughly ₹1.14 lakh crore. The market showed a measured response to the spin-out, reflecting the deal's non-cash nature and Lupin's retained controlling stake.
Kaveri Plans to Raise Capital and Run Independent Trials
Kaveri Therapeutics will seek outside investment to fund clinical development beyond Lupin's initial seed funding. The company plans to run independent global trials for both drug candidates, targeting some of the hardest-to-treat solid tumor types, according to Newswire.
Lupin keeps strategic oversight through its 82.2% majority stake but lets Kaveri operate as a standalone clinical-stage company. This model — spinning out early assets into a funded subsidiary — has grown more common among large pharma firms looking to advance high-risk programs without putting them on the main company's balance sheet.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
41
Reach
53
Topics
A
AnonymousAuthor